Results 61 to 70 of about 1,413 (82)

A novel approach to enhance performance of Linux-TCP Westwood on wireless link

Nirma University International Conference on Engineering, 2013
Divan G. Raimagia, Charvi N. Chanda
semanticscholar   +1 more source

TCP Westwood with adaptive bandwidth estimation to improve efficiency/friendliness tradeoffs

Computer Communications, 2004
M. Gerla, Bryan Kwok, Fai Ng, M. Sanadidi, Massimo Valla, Ren Wang   +5 more
semanticscholar   +1 more source

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial

Nature Medicine, 2020
Nick van Dijk, Alberto Gil-Jimenez, Karina Silina   +2 more
exaly  

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature Medicine, 2023
Vivek Subbiah, Ulrik Lassen, J-Y Blay
exaly  

Performance evaluation of TCP-Reno, TCP-Newreno and TCP-Westwood on burstification in an OBS network

2012 18th International Conference on Advanced Computing and Communications (ADCOM), 2012
R. Pavani, N. Sreenath
semanticscholar   +1 more source

INET framework extensions for TCP Vegas and TCP Westwood: poster abstract

International ICST Conference on Simulation Tools and Techniques, 2013
María Fernández, C. Calafate, Juan-Carlos Cano, P. Manzoni   +3 more
semanticscholar   +1 more source

Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma

Nature Medicine, 2020
Jianjun Gao, Omar Alhalabi, Arlene O Siefker-Radtke   +2 more
exaly  

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Lancet, The, 2021
Jong-Mu Sun, Manish A Shah, Toshihiko Doi   +2 more
exaly  

TCP Westwood+ Enhancement in High-Speed Long-Distance Networks

IEEE International Conference on Communications, 2006
D. Kliazovich, F. Granelli, D. Miorandi
semanticscholar   +1 more source

First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial

Nature Medicine, 2023
Bo Zhang, Jing Huang
exaly